

James P Allison

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1907143/james-p-allison-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

276
papers

64,980
citations

116
h-index

254
g-index

283
ext. papers

75,616
ext. citations

16
avg, IF

8.03
L-index

#	Paper	IF	Citations
276	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.. <i>Science Translational Medicine</i> , 2022 , 14, eabm6420	17.5	0
275	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.. <i>Cancer Cell</i> , 2022 , 40, 509-523.e6	24.3	10
274	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , 2021 , 374, 1632-1640	33.3	52
273	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021 , 12, 6071	17.4	5
272	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment 2021 , 9,		3
271	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 3556-3566	12.9	10
270	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021 , 11, 838-857	24.4	76
269	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	8
268	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2021 , 27, 4557-4565	12.9	8
267	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441	50.5	57
266	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021 , 11, 614-625	24.4	49
265	Frontiers in cancer immunotherapy-a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021 , 1489, 30-47	6.5	10
264	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021 , 27, 504-514	50.5	105
263	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 5045	17.4	6
262	Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. <i>Blood Cancer Discovery</i> , 2021 , 2, 551-554	7	1
261	mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	37
260	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	54

259	Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. <i>Blood</i> , 2020 , 136, 29-31	2.2	
258	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020 , 136, 43-45	2.2	0
257	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. <i>JCI Insight</i> , 2020 , 5,	9.9	88
256	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020 , 11, 603	17.4	67
255	Dissecting the mechanisms of immune checkpoint therapy. <i>Nature Reviews Immunology</i> , 2020 , 20, 75-76	36.5	141
254	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020 , 26, 39-46	50.5	119
253	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020 , 26, 1845-1851	50.5	72
252	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020 , 11, 1839	17.4	9
251	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22699-22709	11.5	119
250	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response. <i>Clinical Cancer Research</i> , 2019 , 25, 3469-3470	12.9	32
249	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 10453-10462	11.5	29
248	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 147-164	7.1	248
247	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. <i>Immunity</i> , 2019 , 50, 1084-1098.e10	32.3	43
246	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 1233-1238	12.9	161
245	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2019 , 7, 1390-1395	12.5	30
244	Characterization and Comparison of GTR Expression in Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 6501-6510	12.9	14
243	Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. <i>Cancer Immunology Research</i> , 2019 , 7, 1803-1812	12.5	21
242	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22246-22251	11.5	74

241	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019 , 4,	9.9	7
240	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. <i>Blood</i> , 2019 , 134, 830-830	2.2	21
239	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019 , 7, 1903-1909	12.5	44
238	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019 , 9, 370-383	24.4	228
237	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018 , 6, 189-200	12.5	84
236	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2018 , 24, 1011-1018	12.9	28
235	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018 , 359, 97-103	33.3	1895
234	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018 , 8, 1069-1086	34.4	1297
233	Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3813-3818	15.9	109
232	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018 , 132, 905-905	2.2	19
231	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. <i>Blood</i> , 2018 , 132, 906-906	2.2	11
230	A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. <i>Blood</i> , 2018 , 132, 296-296	2.2	20
229	Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Blood</i> , 2018 , 132, 4585-4585	2.2	1
228	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018 , 24, 1804-1808	50.5	297
227	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017 , 5, 100-105	12.5	37
226	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	409
225	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. <i>Nature Communications</i> , 2017 , 8, 14340	17.4	80
224	Cancer Immunotherapy 2017 , 1-23		

223	Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. <i>Nature Communications</i> , 2017 , 8, 15095	17.4	255
222	Fc Gamma R 2017 , 209-228		
221	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. <i>Nature Medicine</i> , 2017 , 23, 551-555	50.5	316
220	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017 , 2,	6.2	82
219	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017 , 8, 451	17.4	72
218	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017 , 7, 1088-1097	24.4	105
217	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017 , 170, 1120-1133.e17	56.2	659
216	Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. <i>Journal of Immunology</i> , 2017 , 199, 974-981	5.3	5
215	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <i>Cancer Research</i> , 2017 , 77, 839-850	10.1	145
214	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016 , 22, 5729-5737	12.9	109
213	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016 , 4, 835-844	12.5	95
212	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016 , 7, 12632	17.4	408
211	Loss of IFN- β Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <i>Cell</i> , 2016 , 167, 397-404.e9	56.2	688
210	Interdependent IL-7 and IFN- β Signalling in T-cell controls tumour eradication by combined CTLA-4+PD-1 therapy. <i>Nature Communications</i> , 2016 , 7, 12335	17.4	63
209	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016 , 6, 827-37	24.4	561
208	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>OncImmunology</i> , 2016 , 5, e1136044	7.2	42
207	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 81	22.4	46
206	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , 2016 , 4, 279-88	12.5	22

205	ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. <i>Cancer Research</i> , 2016 , 76, 3684-9	10.1	41
204	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 11919-11924	11.5	127
203	Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. <i>Nature Medicine</i> , 2015 , 21, 998-1009	50.5	546
202	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , 2015 , 5, 860-77	24.4	476
201	The future of immune checkpoint therapy. <i>Science</i> , 2015 , 348, 56-61	33.3	2733
200	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015 , 125, 3335-46	2.2	46
199	Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. <i>Cell</i> , 2015 , 161, 205-14	56.2	1388
198	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , 2015 , 13, 412-24	10.6	275
197	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E5290-9	11.5	59
196	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. <i>Cancer Immunology Research</i> , 2015 , 3, 849-54	12.5	27
195	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015 , 7, 967-980	3.8	64
194	Checkpoints. <i>Cell</i> , 2015 , 162, 1202-5	56.2	21
193	Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBaKey Clinical Medical Research Award. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1113-4	27.4	53
192	Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. <i>Journal of Immunology</i> , 2015 , 194, 2089-98	5.3	33
191	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
190	Vaccination with tumor cells expressing IL-15 and IL-15R α inhibits murine breast and prostate cancer. <i>Gene Therapy</i> , 2014 , 21, 393-401	4	25
189	Immune modulation in cancer with antibodies. <i>Annual Review of Medicine</i> , 2014 , 65, 185-202	17.4	366
188	Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. <i>Cancer Immunology Research</i> , 2014 , 2, 831-8	12.5	226

187	Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2014 , 211, 715-25	16.6	186
186	Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. <i>Cancer Cell</i> , 2014 , 25, 719-34	24.3	1332
185	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014 , 515, 577-81	50.4	1331
184	Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. <i>Science Translational Medicine</i> , 2014 , 6, 226ra32	17.5	484
183	Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. <i>Cancer Immunology Research</i> , 2014 , 2, 970-80	12.5	55
182	Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3106-11	3.1	39
181	Immune Co-signaling to Treat Cancer 2013 , 211-280		1
180	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. <i>Clinical Cancer Research</i> , 2013 , 19, 6112-25	12.9	50
179	Aire-dependent thymic development of tumor-associated regulatory T cells. <i>Science</i> , 2013 , 339, 1219-24	33.3	230
178	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <i>Annals of the New York Academy of Sciences</i> , 2013 , 1291, 1-13	6.5	215
177	Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. <i>Cancer Immunology Research</i> , 2013 , 1, 229-34	12.5	149
176	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. <i>Journal of Experimental Medicine</i> , 2013 , 210, 743-55	16.6	111
175	Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. <i>Cancer Immunology Research</i> , 2013 , 1, 235-44	12.5	75
174	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1695-710	16.6	948
173	Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. <i>Journal of Immunology</i> , 2013 , 190, 526-30	5.3	6
172	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1389-402	16.6	452
171	Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF- κ B signaling improves the efficacy of immunotherapy in a brain cancer model. <i>Neurotherapeutics</i> , 2012 , 9, 827-43	6.4	29
170	Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". <i>Immunobiology</i> , 2012 , 217, 590-2	3.4	9

169	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012 , 10, 205	8.5	538
168	Immunologic correlates of the abscopal effect in a patient with melanoma. <i>New England Journal of Medicine</i> , 2012 , 366, 925-31	59.2	1503
167	Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 881-6	11.5	63
166	Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. <i>PLoS ONE</i> , 2012 , 7, e35222	3.7	4
165	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. <i>Nature</i> , 2012 , 482, 400-4	50.4	849
164	Response to Comment on Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells	5.3	3
163	Augmented IL-15R α expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. <i>Journal of Immunology</i> , 2012 , 188, 6156-64	5.3	38
162	Cutting edge: CTLA-4 on effector T cells inhibits in trans. <i>Journal of Immunology</i> , 2012 , 189, 1123-7	5.3	82
161	B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. <i>Journal of Immunology</i> , 2012 , 189, 4165-74	5.3	26
160	Expression of Helios in peripherally induced Foxp3+ regulatory T cells. <i>Journal of Immunology</i> , 2012 , 188, 976-80	5.3	229
159	Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. <i>Cancer Research</i> , 2012 , 72, 430-9	10.1	205
158	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6187-92	11.5	77
157	Retrospective. Lloyd J. Old (1933-2011). <i>Science</i> , 2012 , 335, 49	33.3	
156	CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. <i>Oncotarget</i> , 2012 , 1, 544-546	7.2	28
155	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdO. <i>Nature Medicine</i> , 2011 , 17, 1094-100	50.5	402
154	Nobels: Toll pioneers deserve recognition. <i>Nature</i> , 2011 , 479, 178	50.4	4
153	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , 2011 , 241, 104-18	11.3	185
152	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. <i>Nature Reviews Cancer</i> , 2011 , 11, 805-12	31.3	460

151	CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1137-46	7.4	74
150	T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF- β cytokine. <i>Immunity</i> , 2011 , 35, 123-34	32.3	91
149	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 16723-8	11.5	270
148	Strength of TCR-peptide/MHC interactions and in vivo T cell responses. <i>Journal of Immunology</i> , 2011 , 186, 5039-45	5.3	137
147	Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1683-94	16.6	47
146	Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 266-71	11.5	122
145	Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. <i>PLoS ONE</i> , 2011 , 6, e19499	3.7	168
144	Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. <i>Clinical Cancer Research</i> , 2010 , 16, 2781-91	12.9	108
143	TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. <i>Journal of Experimental Medicine</i> , 2010 , 207, 1701-11	16.6	207
142	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. <i>Clinical Cancer Research</i> , 2010 , 16, 2861-71	12.9	347
141	Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. <i>Journal of Experimental Medicine</i> , 2010 , 207, 637-50	16.6	559
140	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 4275-80	11.5	1276
139	Attenuated T cell responses to a high-potency ligand in vivo. <i>PLoS Biology</i> , 2010 , 8, e1000481	9.7	73
138	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. <i>Modern Pathology</i> , 2010 , 23, 1104-12	9.8	162
137	Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). <i>Current Opinion in Immunology</i> , 2010 , 22, 326-32	7.8	158
136	Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. <i>Seminars in Oncology</i> , 2010 , 37, 473-84	5.5	184
135	Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. <i>Cancer</i> , 2010 , 116, 1767-75	6.4	364
134	Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. <i>Cancer Research</i> , 2009 , 69, 7747-55	10.1	101

133	Inhibitors of B7-CD28 costimulation in urologic malignancies. <i>Immunotherapy</i> , 2009 , 1, 129-39	3.8	9
132	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1717-25	16.6	677
131	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. <i>Clinical and Experimental Immunology</i> , 2009 , 157, 9-19	6.2	111
130	Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. <i>Immunological Reviews</i> , 2009 , 229, 67-87	11.3	126
129	The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. <i>Clinical Cancer Research</i> , 2009 , 15, 5323-37	12.9	960
128	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. <i>Cytotherapy</i> , 2009 , 11, 912-22	4.8	30
127	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 20410-5	11.5	291
126	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3509-14	11.5	42
125	Epitope landscape in breast and colorectal cancer. <i>Cancer Research</i> , 2008 , 68, 889-92	10.1	328
124	Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. <i>Science</i> , 2008 , 319, 215-20	33.3	82
123	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3005-10	11.5	533
122	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. <i>Journal of Experimental Medicine</i> , 2008 , 205, 2125-38	16.6	167
121	Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. <i>Cancer Research</i> , 2008 , 68, 6054-8	10.1	65
120	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. <i>Blood</i> , 2008 , 112, 1175-83	2.2	196
119	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1263-70	7.4	47
118	Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. <i>Immunological Reviews</i> , 2008 , 224, 141-65	11.3	182
117	The B7 family and cancer therapy: costimulation and coinhibition. <i>Clinical Cancer Research</i> , 2007 , 13, 5271-9	12.9	277
116	Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. <i>Cancer Cell</i> , 2007 , 12, 192-9	24.3	55

115	Immunotherapeutic strategies for high-risk bladder cancer. <i>Seminars in Oncology</i> , 2007 , 34, 165-72	5.5	27
114	Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. <i>Journal of Immunology</i> , 2007 , 179, 3926-36	5.3	214
113	A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 1810-5	12.9	338
112	Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 17765-70	11.5	73
111	Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. <i>Clinical Cancer Research</i> , 2007 , 13, 2158-67	12.9	235
110	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19458-63	11.5	283
109	Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulinitis and destruction of beta cells. <i>Blood</i> , 2007 , 110, 954-61	2.2	23
108	T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. <i>Immunity</i> , 2007 , 26, 311-21	32.3	148
107	Checkpoint Blockade and Combinatorial Immunotherapies 2007 , 363-390		
106	CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. <i>Journal of Immunology</i> , 2006 , 177, 1052-61	5.3	91
105	Checkpoint blockade in cancer immunotherapy. <i>Advances in Immunology</i> , 2006 , 90, 297-339	5.6	414
104	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. <i>Genomics</i> , 2006 , 88, 841-845	4.3	10
103	Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 442-7	2.8	37
102	Restoring function in exhausted CD8 T cells during chronic viral infection. <i>Nature</i> , 2006 , 439, 682-7	50.4	2903
101	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2006 , 18, 206-13	7.8	367
100	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1935-45	15.9	531
99	To be or not to be B7. <i>Journal of Clinical Investigation</i> , 2006 , 116, 2590-3	15.9	16
98	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. <i>British Journal of Haematology</i> , 2005 , 130, 809-24	4.5	37

97	Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 9872-7	11.5	20
96	Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. <i>Journal of Immunology</i> , 2005 , 175, 4199-207	5.3	42
95	Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. <i>Journal of Immunology</i> , 2005 , 174, 1922-31	5.3	84
94	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 728-34	12.9	622
93	B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. <i>Journal of Immunology</i> , 2004 , 172, 34-9	5.3	109
92	MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). <i>International Immunology</i> , 2004 , 16, 895-904	4.9	7
91	Augmentation of T cell levels and responses induced by androgen deprivation. <i>Journal of Immunology</i> , 2004 , 173, 6098-108	5.3	188
90	Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. <i>Arthritis Research</i> , 2004 , 6, 208-14		18
89	CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. <i>Vaccine</i> , 2004 , 22, 1700-8	4.1	104
88	B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. <i>Immunity</i> , 2004 , 21, 401-13	32.3	331
87	CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. <i>Blood</i> , 2004 , 103, 4594-601	2.2	68
86	B7x: a widely expressed B7 family member that inhibits T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10388-92	11.5	317
85	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8372-7	11.5	1325
84	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. <i>Nature Immunology</i> , 2003 , 4, 670-9	19.1	644
83	Prostate cancer: advances in immunotherapy. <i>BioDrugs</i> , 2003 , 17, 131-8	7.9	11
82	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 4712-7	11.5	829
81	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 5336-41	11.5	452
80	Protein Localization in Negative Signaling 2003 , 355-359		

79	CTLA-4: new insights into its biological function and use in tumor immunotherapy. <i>Nature Immunology</i> , 2002 , 3, 611-8	19.1	735
78	Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 3013-7	11.5	58
77	Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. <i>Journal of Immunology</i> , 2002 , 169, 4094-7	5.3	46
76	The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. <i>Blood</i> , 2002 , 99, 4509-16	2.2	9
75	Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. <i>Immunity</i> , 2002 , 16, 23-35	32.3	406
74	ICOS co-stimulatory receptor is essential for T-cell activation and function. <i>Nature</i> , 2001 , 409, 97-101	50.4	742
73	Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. <i>Journal of Experimental Medicine</i> , 2001 , 194, 823-32	16.6	885
72	Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 2587-92	11.5	48
71	CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. <i>Annual Review of Immunology</i> , 2001 , 19, 565-94	34.7	759
70	Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. <i>Journal of Experimental Medicine</i> , 2001 , 194, 481-9	16.6	274
69	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 12711-6	11.5	61
68	Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 12204-9	11.5	90
67	The role of B7 costimulation in CD4/CD8 T cell homeostasis. <i>Journal of Immunology</i> , 2000 , 164, 3543-53	5.3	48
66	Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. <i>Journal of Autoimmunity</i> , 2000 , 14, 123-31	15.5	14
65	In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 11476-81	11.5	139
64	Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 15074-9	11.5	195
63	Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. <i>Journal of Experimental Medicine</i> , 1999 , 190, 355-66	16.6	840
62	Costimulatory regulation of T cell function. <i>Current Opinion in Cell Biology</i> , 1999 , 11, 203-10	9	330

61	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 8603-8	11.5	107
60	Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. <i>Journal of Experimental Medicine</i> , 1998 , 187, 427-32	16.6	250
59	Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. <i>Journal of Experimental Medicine</i> , 1998 , 188, 651-9	16.6	73
58	CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 10067-71	11.5	334
57	Itk negatively regulates induction of T cell proliferation by CD28 costimulation. <i>Journal of Experimental Medicine</i> , 1997 , 186, 221-8	16.6	44
56	Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 9273-8	11.5	167
55	Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 8099-103	11.5	321
54	T cell-mediated elimination of B7.2 transgenic B cells. <i>Immunity</i> , 1997 , 6, 327-39	32.3	41
53	The emerging role of CTLA-4 as an immune attenuator. <i>Immunity</i> , 1997 , 7, 445-50	32.3	542
52	Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. <i>Immunity</i> , 1997 , 7, 885-95	32.3	324
51	Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1997 , 73, 57-62	3.5	86
50	Thymocyte development is normal in CTLA-4-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 9296-301	11.5	131
49	Lymphocyte activation and effector functions. How signals are integrated in the immune system. <i>Current Opinion in Immunology</i> , 1997 , 9, 293-5	7.8	2
48	Co-stimulation in T cell responses. <i>Current Opinion in Immunology</i> , 1997 , 9, 396-404	7.8	372
47	Enhancement of antitumor immunity by CTLA-4 blockade. <i>Science</i> , 1996 , 271, 1734-6	33.3	2546
46	The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. <i>European Journal of Immunology</i> , 1996 , 26, 3224-9	6.1	23
45	CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. <i>Journal of Experimental Medicine</i> , 1996 , 183, 2533-40	16.6	756
44	Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. <i>International Immunology</i> , 1996 , 8, 519-23	4.9	119

43	Manipulation of costimulatory signals to enhance antitumor T-cell responses. <i>Current Opinion in Immunology</i> , 1995 , 7, 682-6	7.8	140
42	CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. <i>Journal of Experimental Medicine</i> , 1995 , 182, 459-65	16.6	1595
41	The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. <i>Immunity</i> , 1995 , 3, 439-47	32.3	49
40	The Yin and Yang of T cell costimulation. <i>Science</i> , 1995 , 270, 932-3	33.3	157
39	CD28-B7 interactions in T-cell activation. <i>Current Opinion in Immunology</i> , 1994 , 6, 414-9	7.8	271
38	CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. <i>Journal of Experimental Medicine</i> , 1993 , 177, 1791-6	16.6	243
37	Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. <i>International Immunology</i> , 1993 , 5, 1451-60	4.9	14
36	T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. <i>International Immunology</i> , 1993 , 5, 145-53	4.9	54
35	Activation and differentiation requirements of primary T cells in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 8987-91	11.5	82
34	Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. <i>Journal of Experimental Medicine</i> , 1993 , 177, 1061-70	16.6	21
33	Intrathymic differentiation of V gamma 3 T cells. <i>Journal of Experimental Medicine</i> , 1993 , 178, 309-15	16.6	42
32	Gamma delta T-cell development. <i>Current Opinion in Immunology</i> , 1993 , 5, 241-6	7.8	48
31	CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. <i>Nature</i> , 1992 , 356, 607-9	50.4	1346
30	Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. <i>International Immunology</i> , 1991 , 3, 385-93	4.9	20
29	Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. <i>Nature</i> , 1990 , 344, 68-70	50.4	267
28	Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. <i>Nucleic Acids Research</i> , 1990 , 18, 7153	20.1	4
27	Diminished expression of the T cell receptor on the expanded lymphocyte population in MRL/Mp-lpr/lpr mice. <i>Autoimmunity</i> , 1989 , 2, 97-111	3	9
26	Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. <i>European Journal of Immunology</i> , 1989 , 19, 857-63	6.1	26

25	Characterization of env gene recombination in x-ray--induced thymomas of C57BL/6 mice. <i>Molecular Carcinogenesis</i> , 1989 , 2, 126-30	5	3
24	Gamma delta antigen receptors of Thy-1+ dendritic epidermal cells: implications for thymic differentiation. <i>Immunologic Research</i> , 1988 , 7, 292-302	4.3	7
23	Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. <i>Cell</i> , 1988 , 55, 837-47	56.2	495
22	The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. <i>Journal of Experimental Medicine</i> , 1987 , 165, 1076-94	16.6	156
21	A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. <i>Cell</i> , 1987 , 49, 143-51	56.2	64
20	Structure, function, and serology of the T-cell antigen receptor complex. <i>Annual Review of Immunology</i> , 1987 , 5, 503-40	34.7	212
19	The gamma T-cell antigen receptor. <i>Journal of Clinical Immunology</i> , 1987 , 7, 429-40	5.7	20
18	The T-cell antigen receptor gamma gene: rearrangement and cell lineages. <i>Trends in Immunology</i> , 1987 , 8, 293-6		59
17	The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. <i>Cellular Immunology</i> , 1986 , 101, 586-92	4.4	
16	Identification of antigen receptor-associated structures on murine T cells. <i>Nature</i> , 1985 , 314, 107-9	50.4	79
15	Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. <i>Experimental Cell Research</i> , 1985 , 158, 509-18	4.2	49
14	Structural differences in envelope glycoproteins associated with rat leukaemia virus produced by Novikoff hepatocellular carcinoma and spontaneously transformed Wistar rat embryo cells. <i>Journal of General Virology</i> , 1984 , 65 (Pt 4), 743-60	4.9	
13	The murine T cell antigen receptor and associated structures. <i>Immunological Reviews</i> , 1984 , 81, 145-60	11.3	25
12	Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. <i>Experimental Cell Research</i> , 1984 , 152, 402-14	4.2	22
11	Biosynthesis and processing of murine T-cell antigen receptor. <i>Cell</i> , 1984 , 38, 659-65	56.2	25
10	HLA antigens in serum. <i>Methods in Enzymology</i> , 1984 , 108, 614-24	1.7	30
9	Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. <i>Immunogenetics</i> , 1983 , 17, 655-9	3.2	2
8	The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. <i>Cell</i> , 1983 , 34, 739-46	56.2	204

7	Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. <i>Developmental Biology</i> , 1982 , 91, 389-96	3.1	18
6	H-2 antigens on a murine lymphoma are associated with additional proteins. <i>Nature</i> , 1978 , 271, 165-7	50.4	27
5	Murine Ia and human DR antigens: homology of amino-terminal sequences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1978 , 75, 3953-6	11.5	100
4	Training procedures and task difficulty in brightness and position discriminations by rats. <i>Psychological Reports</i> , 1972 , 31, 71-6	1.6	1
3	Insolubilization of L-asparaginase by covalent attachment to nylon tubing. <i>Biochemical and Biophysical Research Communications</i> , 1972 , 47, 66-73	3.4	53
2	The substrate specificity of L-asparaginase from <i>Alcaligenes eutrophus</i> . <i>FEBS Letters</i> , 1971 , 14, 107-108	3.8	14
1	Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy		1